Yingchao Wu

Dr. Yingchao Wu

Department of Breast, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Closed access
Yingchao WuYingchao Wu
Yingchao Wu
DPDajin Pi
Dajin Pi
SZShuyao Zhou
Shuyao Zhou
ZYZhongjia Yi
Zhongjia Yi
YDYangyang Dong
Yangyang Dong
MOMingzi Ouyang
Mingzi Ouyang
Ginsenoside Rh3 (GRh3) is a seminatural product obtained by chemical processing after isolation from Chinese herbal medicine that has strong antitumor activity against human tumors. However, its antitumor role remains to be elucidated. The aim of this study is to explore the mechanisms underlying the tumor suppressive activity of GRh3 from the perspective of pyroptosis and ferroptosis. GRh3 eliminates colorectal cancer (CRC) cells by activating gasdermin D (GSDMD)-dependent pyroptosis and suppressing solute carrier family 7 member 11 (SLC7A11), resulting in ferroptosis activation through the Stat3/p53/NRF2 axis. GRh3 suppresses nuclear factor erythroid 2-related factor 2 (NRF2) entry into the nucleus, leading to the decrease of heme oxygenase 1 (HO-1) expression, which in turn promotes NOD-like receptor thermal protein domain associated protein 3 (NLRP3) and caspase-1 expression. Finally, caspase-1 activates GSDMD-dependent pyroptosis. Furthermore, GRh3 prevents NRF2 from entering the nucleus, which suppresses SLC7A11, causing the depletion of glutathione (GSH) and accumulation of iron, lipid reactive oxygen species (ROS) and malondialdehyde (MDA), and eventually leading to ferroptosis in CRC cells. In addition, GRh3 effectively inhibits the proliferation of CRC cells in vitro and in nude mouse models. Collectively, GRh3 triggers pyroptotic cell death and ferroptotic cell death in CRC cells via the Stat3/p53/NRF2 axis with minimal harm to normal cells, showing great anticancer potential.

1 January 2023 in Integrative Cancer Therapies
Verified
Journal Article
Open access
Yingchao WuYingchao Wu
Yingchao Wu
DPDajin Pi
Dajin Pi
SZShuyao Zhou
Shuyao Zhou
WWWuhong Wang
Wuhong Wang
HYHuan Ye
Huan Ye
MOMingzi Ouyang
Mingzi Ouyang
Background: Cisplatin is a widely used anticancer drug in clinic, but it has a damaging effect on skeletal muscle cells. Clinical observation showed that Yiqi Chutan formula (YCF) had a alleviating effect on cisplatin toxicity. Methods: In vitro cell model and in vivo animal model were used to observe the damage effect of cisplatin on skeletal muscle cells and verify that YCF reversed cisplatin induced skeletal muscle damage. The levels of oxidative stress, apoptosis and ferroptosis were measured in each group. Results: Both in vitro and in vivo studies have confirmed that cisplatin increases the level of oxidative stress in skeletal muscle cells, thus inducing cell apoptosis and ferroptosis. YCF treatment can effectively reverse cisplatin induced oxidative stress in skeletal muscle cells, thereby alleviating cell apoptosis and ferroptosis, and ultimately protecting skeletal muscle. Conclusions: YCF reversed cisplatin-induced apoptosis and ferroptosis of skeletal muscle by alleviating oxidative stress.

24 September 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
Yingchao WuYingchao Wu
Yingchao Wu
YLYuqi Liang
Yuqi Liang
JCJiaqi Cui
Jiaqi Cui
JCJieting Chen
Jieting Chen
JHJunfeng Huang
Junfeng Huang
QCQianjun Chen
Qianjun Chen

21 August 2025 in Natural Products and Bioprospecting
Verified
Journal Article
Open access
PDF file
Yingchao WuYingchao Wu
Yingchao Wu
JCJiaqi Cui
Jiaqi Cui
LCLiushan Chen
Liushan Chen
JCJieting Chen
Jieting Chen
JHJunfeng Huang
Junfeng Huang
QZQian Zuo
Qian Zuo
Background: Depression promotes breast cancer progression. Given the lack of specific targets for depression-associated breast cancer, there are currently no therapeutic drugs for this type of breast cancer. Methods: Transcriptomic analysis was conducted to identify and functionally annotate genes with differential expression in breast cancer patients exhibiting depressive symptoms. Subsequently, Mendelian randomization was employed to investigate the causal associations between these pivotal genes and breast cancer, thereby validating their potential roles as therapeutic targets. Furthermore, molecular docking techniques were utilized to screen for candidate compounds that may exert therapeutic effects on depression-associated breast cancer. The efficacy of the selected compounds was further assessed using both in vitro cellular experiments and in vivo animal models. Results: We identified IL-8 as a key gene involved in depression-mediated breast cancer progression using transcriptomics. Mendelian randomized analysis suggested that high IL-8 expression promoted breast cancer progression. Further studies demonstrated that IL-8 mediated the breast cancer-promoting effect of depression through the receptor CXCR2. Evidence from both in vitro and in vivo experiments indicates that senkyunolide H may exert its therapeutic effect by regulating CXCR2, thereby counteracting the protumor effects associated with depression in breast cancer. Conclusion: Depression activates CXCR2-mediated breast cancer cell proliferation through IL-8, and senkyunolide H regulates CXCR2 and inhibits its ability to block the cancer-promoting effects of depression, ultimately inhibiting the growth of breast cancer in the context of depression. Graphical

25 April 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Yingchao WuYingchao Wu
Yingchao Wu
LCLiushan Chen
Liushan Chen
DPDajin Pi
Dajin Pi
JCJiaqi Cui
Jiaqi Cui
YLYuqi Liang
Yuqi Liang
QZQian Zuo
Qian Zuo
Background: Breast cancer has now become the most prevalent cancer worldwide. Existing therapeutic agents are generally accompanied by significant side effects. Here, we highlight Saikosaponin A (SSA), a promising natural metabolite characterized by low toxicity, demonstrating significant efficacy against breast cancer through the induction of cellular senescence.Methods: The antitumor property of SSA was determined via MTT colorimetric assay, 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay, colony formation, and propidium iodide (PI) staining in vitro, as well as xenograft in vivo model. A network approach was used to predict potential targets of SSA reevant for a potential anti-tumor effect and verified through senescence-associated β-galactosidase (SA-β-gal), flow-cytometry analysis, RT-PCR, Western blotting, and immuno-histochemistry assay.Results: SSA significantly suppressed proliferation and triggered cell cycle arrest of SUM159PT and MDA-MB-231 cells. Revealed by network analysis, cellular senescence, and phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway were implemented in the anti-tumor effects of SSA. SSA-stimulated senescence was associated with increased ROS production, distinct senescence-associated secretory phenotype (SASP), and restricted PI3K/Akt signaling, as well as p21 and p53 accumulation. Furthermore, SSA displayed inhibitory effects on tumor growth with minimal toxicity in animal studies, accompanied by activated biomarkers of cellular senescence and decreased expression of p-Akt and p-PI3K.Conclusion: Taken together, based on the preliminary results of network analysis and further experimental validation, this study revealed that SSA significantly induced cell cycle arrest and senescence, and the inhibition of ROS-mediated PI3K/Akt pathway may be the potential mechanism in this process.

20 November 2024 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
Yingchao WuYingchao Wu
Yingchao Wu
HWHui Wang
Hui Wang
ZLZheng Liang
Zheng Liang
JCJiaqi Cui
Jiaqi Cui
SLSiyan Liu
Siyan Liu
MOMingzi Ouyang
Mingzi Ouyang
Cisplatin (DDP) is widely used to treat clinical malignant tumors, but it is also accompanied by serious adverse reactions, such as brain nervous system injury. In clinical treatment and animal experiments, traditional Chinese medicine formula (Yifei-sanjie Pill, YFSJ) has been observed to relieve the symptoms of chemobrain caused by DDP chemotherapy, but its mechanism of action remains unclear. A subcutaneous model of non-small cell lung cancer was established in mice, which were subsequently treated with YFSJ to evaluate the mechanism by which YFSJ alleviates DDP-induced chemobrain. Specifically, the effects of DDP and YFSJ on the brain nervous system of mice were evaluated by behavioral tests, brain blood flow observation, network pharmacology analysis, and histological analysis. In addition, the damaging effect of DDP on neurons and the effect of YFSJ on neurons were verified by in vitro experiments. YFSJ reduced systemic inflammation in tumor-bearing mice, restored the function of the blood‒brain barrier (BBB) to reduce the amount of cisplatin in the brain, alleviated the decreases in voluntary activity and brain blood flow microcirculation induced by DDP, and alleviated brain tissue pyroptosis and ferroptosis caused by DDP. YFSJ maintains the functional stability of the BBB by inhibiting tumor-induced inflammation, thereby preventing chemobrain induced by nervous system damage caused by DDP entering brain tissue.